Our multicenter study of 346 CRC patients revealed significantly higher ERCC1 and DPYD expression in patients receiving oxaliplatin as a first-line chemotherapy than in patients receiving no chemotherapy. Here, ERCC1 is linked to colorectal carcinoma.